Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: August 19, 2022

Investigational Drug Information for Masitinib

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the drug development status for Masitinib?

Masitinib is an investigational drug.

There have been 36 clinical trials for Masitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 25^th 2008.

The most common disease conditions in clinical trials are Sclerosis, Mastocytosis, and Gastrointestinal Stromal Tumors. The leading clinical trial sponsors are AB Science and [disabled in preview].

Summary for Masitinib

US Patents	0
International Patents	0
US Patent Applications	902
WIPO Patent Applications	709
Japanese Patent Applications	240
Clinical Trial Progress	Phase 3 (2008-11-25)
Vendors	87

Recent Clinical Trials for Masitinib

Title	Sponsor	Phase
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome	AB Science	Phase 2
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis	AB Science	Phase 3
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19	AB Science	Phase 2

See all Masitinib clinical trials

Clinical Trial Summary for Masitinib

Top disease conditions for Masitinib

Top clinical trial sponsors for Masitinib

See all Masitinib clinical trials

US Patents for Masitinib

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Dow

McKinsey

Medtronic

AstraZeneca

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.